Development of Galectin-3 Targeting Drugs for Therapeutic Applications in Various Diseases

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 May 13

PMID 37175823

Authors

Rakin Ahmed

Khairul Anam

Hafiz Ahmed

Affiliations

Soon will be listed here.

Abstract

Galectin-3 (Gal3) is one of the most studied members of the galectin family that mediate various biological processes such as growth regulation, immune function, cancer metastasis, and apoptosis. Since Gal3 is pro-inflammatory, it is involved in many diseases that are associated with chronic inflammation such as cancer, organ fibrosis, and type 2 diabetes. As a multifunctional protein involved in multiple pathways of many diseases, Gal3 has generated significant interest in pharmaceutical industries. As a result, several Gal3-targeting therapeutic drugs are being developed to address unmet medical needs. Based on the PubMed search of Gal3 to date (1987-2023), here, we briefly describe its structure, carbohydrate-binding properties, endogenous ligands, and roles in various diseases. We also discuss its potential antagonists that are currently being investigated clinically or pre-clinically by the public and private companies. The updated knowledge on Gal3 function in various diseases could initiate new clinical or pre-clinical investigations to test therapeutic strategies, and some of these strategies could be successful and recognized as novel therapeutics for unmet medical needs.

Citing Articles

Metformin dosage and galectin-3 levels: insights from PCOS patients preparing for IVF.

Nikolic V, Stefanovic M, Mitic D, Sunaric S, Stojiljkovic V, Trajkovic H Front Pharmacol. 2025; 15:1505022.

PMID: 39958874 PMC: 11825798. DOI: 10.3389/fphar.2024.1505022.

Elevated Galectin-3 levels in the tumor microenvironment of ovarian cancer - implication of ROS mediated suppression of NK cell antitumor response via tumor-associated neutrophils.

Karlsson V, Stal E, Stoopendahl E, Ivarsson A, Leffler H, Lycke M Front Immunol. 2025; 15:1506236.

PMID: 39759523 PMC: 11695286. DOI: 10.3389/fimmu.2024.1506236.

Single‑Dose Pharmacokinetics and Safety of the Oral Galectin‑3 Inhibitor, Selvigaltin (GB1211), in Participants with Hepatic Impairment.

Aslanis V, Gray M, Slack R, Zetterberg F, Tonev D, Phung D Clin Drug Investig. 2024; 44(10):773-787.

PMID: 39358661 DOI: 10.1007/s40261-024-01395-7.

Targeting Myeloid Differentiation Primary Response Protein 88 (MyD88) and Galectin-3 to Develop Broad-Spectrum Host-Mediated Therapeutics against SARS-CoV-2.

Saikh K, Anam K, Sultana H, Ahmed R, Kumar S, Srinivasan S Int J Mol Sci. 2024; 25(15).

PMID: 39125989 PMC: 11313481. DOI: 10.3390/ijms25158421.

Understanding Galectin-3's Role in Diastolic Dysfunction: A Contemporary Perspective.

Hao W, Cheng C, Liu J, Chen H, Chen J, Cheng T Life (Basel). 2024; 14(7).

PMID: 39063659 PMC: 11277993. DOI: 10.3390/life14070906.

References

Bonner J . Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev. 2004; 15(4):255-73. DOI: 10.1016/j.cytogfr.2004.03.006. View

Nakahara S, Raz A . Regulation of cancer-related gene expression by galectin-3 and the molecular mechanism of its nuclear import pathway. Cancer Metastasis Rev. 2007; 26(3-4):605-10. PMC: 3613988. DOI: 10.1007/s10555-007-9095-6. View

Mahendran S, Sethi T . Treatments in idiopathic pulmonary fibrosis: time for a more targeted approach?. QJM. 2012; 105(10):929-34. DOI: 10.1093/qjmed/hcs076. View

Bianchet M, Ahmed H, Vasta G, Amzel L . Soluble beta-galactosyl-binding lectin (galectin) from toad ovary: crystallographic studies of two protein-sugar complexes. Proteins. 2000; 40(3):378-88. DOI: 10.1002/1097-0134(20000815)40:3<378::aid-prot40>3.0.co;2-7. View

Yoshii T, Fukumori T, Honjo Y, Inohara H, Kim H, Raz A . Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J Biol Chem. 2001; 277(9):6852-7. DOI: 10.1074/jbc.M107668200. View

Henderson N, Sethi T . The regulation of inflammation by galectin-3. Immunol Rev. 2009; 230(1):160-71. DOI: 10.1111/j.1600-065X.2009.00794.x. View

Bayes-Genis A, De Antonio M, Vila J, Penafiel J, Galan A, Barallat J . Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. J Am Coll Cardiol. 2013; 63(2):158-66. DOI: 10.1016/j.jacc.2013.07.087. View

Hsu D, Dowling C, Jeng K, Chen J, Yang R, Liu F . Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma. Int J Cancer. 1999; 81(4):519-26. DOI: 10.1002/(sici)1097-0215(19990517)81:4<519::aid-ijc3>3.0.co;2-0. View

Mohammed N, Antonopoulos A, Dell A, Haslam S, Dimitroff C . The pleiotropic role of galectin-3 in melanoma progression: Unraveling the enigma. Adv Cancer Res. 2023; 157:157-193. PMC: 9895887. DOI: 10.1016/bs.acr.2022.06.001. View

10.

Rosenberg I, Cherayil B, Isselbacher K, Pillai S . Mac-2-binding glycoproteins. Putative ligands for a cytosolic beta-galactoside lectin. J Biol Chem. 1991; 266(28):18731-6. View

11.

Yu L . Circulating galectin-3 in the bloodstream: An emerging promoter of cancer metastasis. World J Gastrointest Oncol. 2010; 2(4):177-80. PMC: 2999182. DOI: 10.4251/wjgo.v2.i4.177. View

12.

Machala E, McSharry B, Rouse B, Abendroth A, Slobedman B . Gal power: the diverse roles of galectins in regulating viral infections. J Gen Virol. 2019; 100(3):333-349. DOI: 10.1099/jgv.0.001208. View

13.

Streetly M, Maharaj L, Joel S, Schey S, Gribben J, Cotter F . GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death. Blood. 2010; 115(19):3939-48. PMC: 5292593. DOI: 10.1182/blood-2009-10-251660. View

14.

Demotte N, Bigirimana R, Wieers G, Stroobant V, Squifflet J, Carrasco J . A short treatment with galactomannan GM-CT-01 corrects the functions of freshly isolated human tumor-infiltrating lymphocytes. Clin Cancer Res. 2014; 20(7):1823-33. DOI: 10.1158/1078-0432.CCR-13-2459. View

15.

Dumont P, Berton A, Nagy N, Sandras F, Tinton S, Demetter P . Expression of galectin-3 in the tumor immune response in colon cancer. Lab Invest. 2008; 88(8):896-906. DOI: 10.1038/labinvest.2008.54. View

16.

Zhao J, Zhang F, Liu X, St Ange K, Zhang A, Li Q . Isolation of a lectin binding rhamnogalacturonan-I containing pectic polysaccharide from pumpkin. Carbohydr Polym. 2017; 163:330-336. DOI: 10.1016/j.carbpol.2017.01.067. View

17.

Jeftic I, Jovicic N, Pantic J, Arsenijevic N, Lukic M, Pejnovic N . Galectin-3 Ablation Enhances Liver Steatosis, but Attenuates Inflammation and IL-33-Dependent Fibrosis in Obesogenic Mouse Model of Nonalcoholic Steatohepatitis. Mol Med. 2015; 21:453-65. PMC: 4559528. DOI: 10.2119/molmed.2014.00178. View

18.

Shimonishi T, Miyazaki K, Kono N, Sabit H, Tuneyama K, Harada K . Expression of endogenous galectin-1 and galectin-3 in intrahepatic cholangiocarcinoma. Hum Pathol. 2001; 32(3):302-10. DOI: 10.1053/hupa.2001.22767. View

19.

Yu L, Andrews N, Zhao Q, McKean D, Williams J, Connor L . Galectin-3 interaction with Thomsen-Friedenreich disaccharide on cancer-associated MUC1 causes increased cancer cell endothelial adhesion. J Biol Chem. 2006; 282(1):773-81. DOI: 10.1074/jbc.M606862200. View

20.

Yang R, Hsu D, Liu F . Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci U S A. 1996; 93(13):6737-42. PMC: 39096. DOI: 10.1073/pnas.93.13.6737. View